Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most provided claims about indication and listed contraindications are supported by the supplied label text, but multiple detailed statements about missed doses, dosing timing thresholds (e.g., 12 hours), consequences (viral load remaining undetectable, resistance risk mechanism), and specific side-effect risks from doubling are not supported by the provided prescribing information excerpt.
Category Scores
Accurate Statements
BIKTARVY is indicated as a complete regimen for the treatment of HIV-1 in adults and pediatric patients weighing at least 14 kg: (1) with no antiretroviral treatment history, (2) with prior antiretroviral treatment but not virologically suppressed and no known or suspected substitutions associated with resistance to the integrase strand inhibitor class, emtricitabine, or tenofovir, and (3) to replace the current regimen in those virologically suppressed on a stable regimen with no known or suspected substitutions associated with resistance to bictegravir or tenofovir.
Section 1 (INDICATIONS AND USAGE)
BIKTARVY is contraindicated to be co-administered with dofetilide due to potential increased dofetilide plasma concentrations and associated serious and/or life-threatening events.
Section 4 (CONTRAINDICATIONS)
BIKTARVY is contraindicated to be co-administered with rifampin due to decreased bictegravir plasma concentrations, which may result in loss of therapeutic effect and development of resistance to BIKTARVY.
Section 4 (CONTRAINDICATIONS)
In pregnant individuals, the recommended dosage is one tablet containing 50 mg bictegravir, 200 mg emtricitabine, and 25 mg tenofovir alafenamide taken orally once daily with or without food in virologically-suppressed pregnant individuals on a stable antiretroviral regimen with no known substitutions associated with resistance to any individual components; viral load should be monitored closely because lower exposures were observed during pregnancy.
Section 2.4 (Recommended Dosage in Pregnant Individuals)
Unsupported Statements
Taking a missed dose as soon as the patient remembers on the same day is recommended.
The provided label excerpt does not include missed-dose instructions.
If the next scheduled dose is close (within a few hours), the missed dose should be skipped and the regular schedule resumed.
The provided label excerpt does not include missed-dose instructions.
Never double up to make up for a missed Biktarvy dose.
The provided label excerpt does not include missed-dose/doubling instructions.
Missing doses can reduce drug levels in the blood.
The provided label excerpt does not state the effect of missed doses on drug levels.
Reduced drug levels from missed doses can increase the risk of developing HIV resistance.
The provided label excerpt discusses resistance in the context of drug interactions, but does not state resistance risk specifically from missed doses.
Developing resistance can make HIV treatment less effective long-term.
The provided label excerpt does not state this as a consequence of missed doses/resistance.
Doubling doses can increase the risk of side effects such as nausea.
The provided label excerpt does not link dose doubling to nausea risk.
Doubling doses can increase the risk of side effects such as kidney issues.
The provided label excerpt does not link dose doubling to kidney issue risk.
If the missed dose is less than 12 hours until the next dose (typical once-daily timing), the missed dose should be skipped.
The provided label excerpt does not provide a numeric threshold (e.g., 12 hours) for missed dosing.
Consistency in dosing helps keep viral load undetectable.
The provided label excerpt does not state that consistent dosing helps keep viral load undetectable.
If multiple Biktarvy doses are missed, the patient should contact a doctor or pharmacist right away.
The provided label excerpt does not provide counseling instructions for multiple missed doses.
After multiple missed doses, viral load testing may be performed and the treatment plan may be adjusted.
The provided label excerpt does not describe actions such as viral load testing after missed doses.
The patient should not restart Biktarvy without medical advice after multiple missed doses.
The provided label excerpt does not provide restart instructions after multiple missed doses.
Multiple missed doses increase resistance risk.
The provided label excerpt does not state missed-dose frequency increases resistance risk.
Patients should stick to their routine time zone when possible but prioritize not missing over exact timing.
The provided label excerpt does not address time zone management or missed-dose prioritization.
Side effects from irregular dosing (e.g., headache, fatigue) should be reported.
The provided label excerpt does not mention irregular dosing causing specific symptoms (headache, fatigue) or reporting instructions tied to missed/irregular dosing.
Contradictions
Important Omissions
The label excerpt provided does not include missed-dose instructions; therefore key practical administration guidance from the label cannot be verified against the AI response.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several missed-dose and dose-doubling statements are not supported by the provided label excerpt. While they may be generally plausible, they cannot be confirmed on-label from the supplied prescribing information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Unverified missed-dose and dose-doubling counseling (including specific timing thresholds and adverse-effect implications) is not supported by the provided FDA label excerpt.
Suggested Improvement
Limit claims to on-label content present in the supplied sections (e.g., indications and listed contraindications). Remove or qualify missed-dose instructions and any statements about effects of missed doses/doubling on drug levels, resistance risk, viral load outcomes, and specific adverse reactions unless the full label missed-dose/treatment failure counseling sections are provided.